The treatment for HPP (Hypophosphatasia) which affects ALP (Alkaline phosphatase) levels, specifically focuses on replacing the deficient enzyme. Doctors use a drug called asfotase alfa (Strensiq) to treat HPP that begins in infancy or childhood. This treatment involves administering the medication via injection under the skin.
Asfotase Alfa (Strensiq) Treatment for HPP
Asfotase alfa is a synthetic protein that replaces the missing alkaline phosphatase in bones. Here's a breakdown of the treatment process:
- Administration: Asfotase alfa is given as a shot under the skin.
- Function: The drug acts as a replacement for the deficient ALP.
- Target Patients: It is specifically used for individuals with HPP that manifests during infancy or childhood.
Here's a summary in a table:
| Treatment | Description | Mode of Delivery | Patients Targeted |
|---|---|---|---|
| Asfotase alfa (Strensiq) | Replaces deficient Alkaline Phosphatase (ALP) in the bones | Injection under the skin | Those with HPP starting in infancy or childhood |
This treatment aims to address the underlying issue of low ALP levels in HPP patients, thus improving bone health.
